Clinical trials: Metformin
Type 2 Diabetes Mellitus
Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes
It has been shown in previous study that progressive glycemic deterioration was associated with progressive loss of b-cell function, measured by the decrease in plasma insulin levels, irrespective of the therapy used (diet…
- Trial name
- NCT00367055
- Testing
- rosiglitazone-metformin, Metformin, metformin+ gliclazide
- Volunteers
- 84 people
- Sponsor
- GlaxoSmithKline
Other Conditions That May Be A Focus of Clinical Attention
Genetic Basis for Variation in the Renal Elimination of Metformin
The current study is part of a large multi-investigator grant to look at the pharmacogenetics of a number of membrane transporters.
- Trial name
- NCT00187720
- Testing
- Metformin
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Type 2 Diabetes Mellitus
A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)
The purpose of this study is to evaluate the efficacy and safety of sitagliptin and MK0431A in comparison to a commonly used medication in patients with type 2 diabetes.
- Trial name
- NCT00541450
- Testing
- Comparator: sitagliptin phosphate (sitagliptin), sitagliptin phosphate (+) metformin hydrochloride, Comparator: pioglitazone
- Volunteers
- 492 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM
The purpose of the study is to compare the glycemic effects of delayed-release metformin (Met DR) to placebo in subjects with type 2 diabetes mellitus (T2DM) over 16 weeks.
- Trial name
- NCT02526524
- Testing
- Met DR, Met IR
- Where
- 137 sites in United States, Puerto Rico
- Volunteers
- 571 people
- Sponsor
- Elcelyx Therapeutics, Inc.
Atrial Fibrillation
Metformin as an Adjunctive Therapy to Catheter Ablation in Atrial Fibrillation
This clinical trial is being done to determine if metformin, a drug which is normally used in diabetes, can reduce atrial fibrillation in patients who are having an ablation for atrial fibrillation (AF).
- Trial name
- NCT04625946
- Testing
- Metformin, Recommendations for lifestyle modification., AliveCor
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- University of Michigan
Type 2 Diabetes
Vildagliptin Versus Dapagliflozin on Glucagon
The aim of the study is to assess if vildagliptin and dapagliflozin have dissociated effects on glucagon secretion after a mixed meal ingestion in metformin-treated subjects with type 2 diabetes and whether this is associated…
- Trial name
- NCT02475070
- Testing
- Vildagliptin, Dapagliflozin
- Where
- Sweden
- Volunteers
- 28 people
- Sponsor
- Lund University
Metabolic Syndrome
Exercise Dose and Metformin for Vascular Health in Metabolic Syndrome
Health organizations recommend exercise in an intensity based manner to promote cardiovascular adaptation and prevent disease. Metformin is a common anti-diabetes medication that reduces future type 2 diabetes and cardiovascular…
- Trial name
- NCT03355469
- Testing
- Metformin, Low Intensity Exercise, High Intensity Exercise
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Rutgers University
Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma
Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer
This phase II trial studies how well nivolumab and metformin work in treating patients with microsatellite stable (MSS) stage IV colorectal cancer that has not responded to previous treatment.
- Conditions
- Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer
- Trial name
- NCT03800602
- Testing
- Metformin, Nivolumab
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- Emory University
Type 2 Diabetes Mellitus
Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)
This study will examine the safety and efficacy of the addition of omarigliptin in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin and glimepiride.
- Trial name
- NCT01704261
- Testing
- Omarigliptin, Glimepiride, Metformin
- Volunteers
- 307 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)
This study will assess the safety, tolerability and glucose-lowering efficacy of MK-0893 in participants with type 2 diabetes mellitus.
- Trial name
- NCT02004886
- Testing
- MK-0893, Metformin
- Volunteers
- 74 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension
The objective of the current study is to investigate the safety and efficacy of BI 10773 in 2 different doses compared to Metformin or to Sitagliptin given for 78 weeks in different modalities of treatment in patients with type 2…
- Trial name
- NCT00881530
- Testing
- BI 10773, Metformin, Sitagliptin
- Where
- 137 sites in United States, Austria and 19 more
- Volunteers
- 660 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator
This is a 24 week study comparing the efficacy of four dose levels of INT131 besylate with pioglitazone HCl in patients with type 2 diabetes.
- Trial name
- NCT00631007
- Testing
- INT131 besylate, Pioglitazone HCl
- Where
- 66 sites in United States, Mexico
- Volunteers
- 367 people
- Sponsor
- InteKrin Therapeutics, Inc.
Type 2 Diabetes Mellitus
Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus
This study is designed as a prospective, multi-centre, parallel group, double-blind randomized, placebo-controlled, phase 3 clinical study to evaluate the efficacy and safety of MP-513 (Teneligliptin) in combination with…
- Trial name
- NCT02924064
- Testing
- Teneligliptin 20mg, Metformin ≥ 1000 mg
- Where
- China
- Volunteers
- 247 people
- Sponsor
- Tanabe Pharma Corporation
Colorectal Cancer, Breast Cancer
Exercise and Metformin in Colorectal and Breast Cancer Survivors
Metformin is a medication that is commonly used in the treatment of diabetes. Recently small studies in cancer patients without diabetes suggest that metformin may benefit in lowering insulin levels.
- Trial name
- NCT01340300
- Testing
- Exercise training, Metformin, Educational information
- Where
- 2 sites in United States
- Volunteers
- 139 people
- Sponsor
- Dana-Farber Cancer Institute
Gestational Diabetes
Metformin Versus Insulin in Gestational Diabetes
Gestational diabetes is traditionally treated with insulin. Metformin is a peroral drug used worldwide in the treatment of type 2 diabetes and also in a few studies on patients with gestational diabetes.
- Trial name
- NCT01240785
- Testing
- metformin, insulin
- Volunteers
- 221 people
- Sponsor
- Turku University Hospital
Type 2 Diabetes Mellitus
Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin
Primary Objective: To investigate the effects of repeated subcutaneous doses of lixisenatide 20 μg once daily (QD) as compared to liraglutide 1.2 mg QD or 1.8 mg QD in reducing post-prandial plasma glucose (PPG) assessed as area…
- Trial name
- NCT01596504
- Testing
- Lixisenatide (AVE0010), Liraglutide, Insulin Glargine
- Where
- 8 sites in Germany
- Volunteers
- 142 people
- Sponsor
- Sanofi
Diabetes Mellitus
Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin
A multicenter, randomized, double-blind, placebo-controlled trial will assess the effects of twice-daily subcutaneous injection with exenatide versus treatment with matching placebo injection on abdominal visceral fat content.
- Trial name
- NCT00701935
- Testing
- exenatide
- Where
- 17 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes
The purpose of this study is determine if Metformin XR monotherapy in subjects with type 2 diabetes is non-inferior to Metformin IR monotherapy
- Trial name
- NCT01864174
- Testing
- Metformin XR, Metformin IR
- Where
- 156 sites in United States, Canada and 8 more
- Volunteers
- 1,736 people
- Sponsor
- Bristol-Myers Squibb
Diabetes, Diabetes Mellitus, Type 2
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of insulin degludec/liraglutide in insulin naïve subjects inadequately controlled…
- Trial name
- DUAL™IV (NCT01618162)
- Testing
- insulin degludec/liraglutide
- Where
- 87 sites in United States, Bulgaria and 6 more
- Volunteers
- 435 people
- Sponsor
- Novo Nordisk A/S
Weight Gain
Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth
The purpose of this pilot study is to determine whether starting metformin in conjunction with a second-generation antipsychotic (SGA) and providing information about healthy eating and activity will prevent or reduce the amount…
- Trial name
- PREVENT (NCT00617240)
- Testing
- metformin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of North Carolina, Chapel Hill